Kolexia
Duveau Nicolas Gastro-entérologie
Duveau Nicolas
Gastro-entérologie
Centre Hospitalier de Roubaix
Roubaix, France
30 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Maladie de Crohn Obésité Diarrhée Sténose pathologique COVID-19 Occlusion intestinale Nécrose Perforation intestinale Maladie chronique

Collaborateurs

Voir plus
Nachury Maria
Nachury Maria
Hôpital Huriez, Lille, France
Tavernier Noemie
Tavernier Noemie
Hôpital Guy Chatiliez, Tourcoing, France
Gerard Romain
Gerard Romain
Hôpital Huriez, Lille, France
Branche Julien
Branche Julien
Hôpital Huriez, Lille, France

Industries

Voir plus
Abbvie
16 collaboration(s)
Dernière en 2023
Takeda Pharmaceutical
15 collaboration(s)
Dernière en 2023
Janssen
12 collaboration(s)
Dernière en 2023
Boston Scientific
3 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
COMET: Comparison of Azathioprine to Methotrexate in Combination Therapy With Adalimumab in Crohn's Disease: an Open-label Randomized Controlled Trial
Essai Clinique (CHU Amiens-Picardie)   07 février 2023
P638 Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn’s disease: a GETAID multicentre cohort study
Abstracts of the 18th Congress of ECCO Copenhagen, Denmark, March 1-4, 2023   30 janvier 2023
Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: A GETAID multicentre cohort study.
Alimentary pharmacology & therapeutics   19 décembre 2022
P140 Immunomodulators are protective against severe COVID 19: results from a large multicentre cohort of inflammatory bowel disease patients
Abstracts of the 17th Congress of ECCO Virtual February 16-19, 2022   21 janvier 2022
Steroid-Free Deep Remission at One Year Does Not Prevent Crohn's Disease Progression: Long-Term Data From the TAILORIX Trial.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association   26 novembre 2021
P458 Association between adalimumab serum levels and level of remission in Crohn’s disease
Abstracts of the 15th Congress of ECCO Vienna, Austria, February 12–15, 2020   15 janvier 2020
Radiological Response Is Associated with Better Outcomes and Should Be Considered a Therapeutic Target in Crohn's Disease.
Digestive diseases and sciences   06 décembre 2019
Ustekinumab Serum Trough Levels May Identify Suboptimal Responders to Ustekinumab in Crohn's Disease.
Digestive diseases and sciences   10 octobre 2019
Patients with Crohn's Disease with High Body Mass Index Present More Frequent and Rapid Loss of Response to Infliximab.
Inflammatory bowel diseases   31 mai 2018
Adalimumab dose escalation is effective and well tolerated in Crohn's disease patients with secondary loss of response to adalimumab.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver   14 novembre 2016